{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:54:52Z","timestamp":1789124092417,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1098,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1111\/jth.14626","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T15:48:58Z","timestamp":1567093738000},"page":"1790-1797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Transgender patients and the role of the coagulation clinician"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-6420","authenticated-orcid":false,"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10042","key":"10.1111\/jth.14626_bb0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(16)00683-8","article-title":"Transgender people: health at the margins of society","volume":"388","author":"Winter","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1111\/jth.14626_bb0015","first-page":"484","article-title":"[Morbidity in transsexual patients with cross\u2010gender hormone self\u2010treatment]","volume":"113","author":"Becerra Fern\u00e1ndez","year":"1999","journal-title":"Med Clin (Barc)"},{"issue":"11","key":"10.1111\/jth.14626_bb0020","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender\u2010dysphoric\/gender\u2010incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1111\/jth.14626_bb0025","first-page":"89","article-title":"Updated recommendations from the world professional association for transgender health standards of care","volume":"87","author":"Deutsch","year":"2013","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1111\/jth.14626_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross\u2010sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1111\/jth.14626_bb0035","first-page":"4","article-title":"Effects on coagulation of levonorgestrel\u2010 and desogestrel\u2010containing low dose oral contraceptives: a cross\u2010over study","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1111\/jth.14626_bb0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second\u2010 and third\u2010generation oral contraceptives","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"issue":"9195","key":"10.1111\/jth.14626_bb0045","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low\u2010dose oral contraceptives and acquired resistance to activated protein C: a randomised cross\u2010over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1111\/jth.14626_bb0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jth.12054","article-title":"Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone\u2010binding globulin levels in premenopausal women","volume":"11","author":"Stegeman","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1111\/jth.14626_bb0055","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex hormone\u2010binding globulin as a marker for the thrombotic risk of hormonal contraceptives","volume":"10","author":"Raps","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1111\/jth.14626_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ijgo.12455","article-title":"A systematic review and meta\u2010analysis of venous thrombosis risk among users of combined oral contraception","volume":"141","author":"Dragoman","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1111\/jth.14626_bb0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21059","article-title":"Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use","volume":"83","author":"Pomp","year":"2008","journal-title":"Am J Hematol"},{"issue":"8935","key":"10.1111\/jth.14626_bb0070","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral\u2010contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"issue":"2","key":"10.1111\/jth.14626_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"Pomp","year":"2007","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1111\/jth.14626_bb0080","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"issue":"9382","key":"10.1111\/jth.14626_bb0085","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen\u2010replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"issue":"7655","key":"10.1111\/jth.14626_bb0090","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta\u2010analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/jth.14626_bb0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/01.AOG.0000250968.82370.04","article-title":"Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users","volume":"109","author":"Cole","year":"2007","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1111\/jth.14626_bb0100","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/GME.0000000000000296","article-title":"Hormone therapy and hemostasis among postmenopausal women: a review","volume":"21","author":"Canonico","year":"2014","journal-title":"Menopause"},{"issue":"7","key":"10.1111\/jth.14626_bb0105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jth.14626_bb0110","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case\u2010control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1111\/jth.14626_bb0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross\u2010sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1111\/jth.14626_bb0120","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2012-2030","article-title":"Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens","volume":"97","author":"Seal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1111\/jth.14626_bb0125","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jsxm.2016.09.001","article-title":"Incidence of venous thromboembolism in transgender women receiving oral estradiol","volume":"13","author":"Arnold","year":"2016","journal-title":"J Sex Med"},{"issue":"3","key":"10.1111\/jth.14626_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1111\/jth.14626_bb0135","first-page":"1218","article-title":"Hormone replacement therapy with estradiol and risk of venous thromboembolism\u2013a population\u2010based case\u2010control study","volume":"82","author":"H\u00f8ibraaten","year":"1999","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1111\/jth.14626_bb0140","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male\u2010to\u2010female transsexuals using gonadotropin\u2010releasing hormone agonist","volume":"113","author":"Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1111\/jth.14626_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/cen.13050","article-title":"Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness","volume":"85","author":"Gava","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1111\/jth.14626_bb0150","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1701-2163(16)30342-5","article-title":"Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation","volume":"25","author":"Spitzer","year":"2003","journal-title":"J Obstet Gynaecol Can"},{"issue":"6","key":"10.1111\/jth.14626_bb0155","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1464-410X.2007.06859.x","article-title":"Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database","volume":"99","author":"Seaman","year":"2007","journal-title":"BJU Int"},{"issue":"2","key":"10.1111\/jth.14626_bb0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15532739.2017.1290566","article-title":"Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?","volume":"18","author":"Fung","year":"2017","journal-title":"International Journal of Transgenderism"},{"issue":"11","key":"10.1111\/jth.14626_bb0165","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jsxm.2016.09.012","article-title":"Differential effects of cyproterone acetate vs spironolactone on serum high\u2010density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women","volume":"13","author":"Fung","year":"2016","journal-title":"J Sex Med"},{"issue":"5","key":"10.1111\/jth.14626_bb0170","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/lgbt.2016.0190","article-title":"Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment","volume":"4","author":"Defreyne","year":"2017","journal-title":"LGBT Health"},{"issue":"9190","key":"10.1111\/jth.14626_bb0175","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)03132-3","article-title":"Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications","volume":"354","author":"Poulter","year":"1999","journal-title":"Lancet"},{"issue":"9190","key":"10.1111\/jth.14626_bb0180","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)04394-9","article-title":"Risk of idiopathic venous thromboembolism in users of progestagens alone","volume":"354","author":"Vasilakis","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1111\/jth.14626_bb0185","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1111\/jth.14626_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1373\/clinchem.2018.288316","article-title":"Venous thrombotic risk in transgender women undergoing estrogen therapy: a systematic review and metaanalysis","volume":"65","author":"Khan","year":"2019","journal-title":"Clin Chem"},{"issue":"12","key":"10.1111\/jth.14626_bb0195","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMra1700365","article-title":"Thrombophilia testing and venous thrombosis","volume":"377","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1111\/jth.14626_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2016.1.1","article-title":"Inherited thrombophilia: a double\u2010edged sword","volume":"2016","author":"Middeldorp","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1111\/jth.14626_bb0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2005.05715.x","article-title":"Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high\u2010risk situations: a meta\u2010analysis and cost\u2010effectiveness analysis","volume":"131","author":"Wu","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1111\/jth.14626_bb0210","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.fertnstert.2008.12.017","article-title":"Incidence of thrombophilia and venous thrombosis in transsexuals under cross\u2010sex hormone therapy","volume":"93","author":"Ott","year":"2010","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1111\/jth.14626_bb0215","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: a population\u2010based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1111\/jth.14626_bb0220","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1111\/jth.14626_bb0225","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1111\/jth.14626_bb0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.thromres.2014.10.033","article-title":"Case\u2010fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention","volume":"135","author":"Wu","year":"2015","journal-title":"Thromb Res"},{"issue":"13","key":"10.1111\/jth.14626_bb0235","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1111\/jth.14626_bb0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1111\/jth.14626_bb0245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/asheducation-2018.1.412","article-title":"Elite athletes and anticoagulant therapy: an intermittent dosing strategy","volume":"2018","author":"Moll","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1111\/jth.14626_bb0250","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/AITC201907020","article-title":"Care of the transgender patient","volume":"171","author":"Safer","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1111\/jth.14626_bb0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/cen.12753","article-title":"Endocrine care of transpeople part I. A review of cross\u2010sex hormonal treatments, outcomes and adverse effects in transmen","volume":"83","author":"Meriggiola","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1111\/jth.14626_bb0260","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/jth.14626_bb0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.urology.2018.11.009","article-title":"Medical treatments for hypogonadism do not significantly increase the risk of deep vein thrombosis over general population risk","volume":"124","author":"Kavoussi","year":"2019","journal-title":"Urology"},{"issue":"8","key":"10.1111\/jth.14626_bb0270","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.mayocp.2015.05.012","article-title":"Risk of venous thromboembolism in men receiving testosterone therapy","volume":"90","author":"Baillargeon","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1111\/jth.14626_bb0275","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","article-title":"Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy","volume":"139","author":"Nota","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1111\/jth.14626_bb0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1111\/jth.14626_bb0285","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older","volume":"374","author":"Snyder","year":"2016","journal-title":"Men. N Engl J Med"},{"issue":"3","key":"10.1111\/jth.14626_bb0290","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/andr.12485","article-title":"Prospective evaluation of hematocrit in gender\u2010affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence","volume":"6","author":"Defreyne","year":"2018","journal-title":"Andrology"},{"issue":"2","key":"10.1111\/jth.14626_bb0295","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MED.0000000000000229","article-title":"Advancing methods for US transgender health research","volume":"23","author":"Reisner","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1111\/jth.14626_bb0300","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.conctc.2018.04.005","article-title":"Metabolic and functional changes in transgender individuals following cross\u2010sex hormone treatment: design and methods of the GEnder Dysphoria Treatment in Sweden (GETS) study","volume":"10","author":"Wiik","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"12","key":"10.1111\/jth.14626_bb0305","doi-asserted-by":"crossref","first-page":"e018121","DOI":"10.1136\/bmjopen-2017-018121","article-title":"Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people","volume":"7","author":"Quinn","year":"2017","journal-title":"BMJ Open"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.14626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622027143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622027143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.14626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:24:18Z","timestamp":1761535458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622027143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1538783622027143"],"URL":"https:\/\/doi.org\/10.1111\/jth.14626","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transgender patients and the role of the coagulation clinician","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}